In the first case of securities fraud related to COVID-19 to be brought before a US court, prosecutors charged the president of a California-based medical technology company with defrauding investors, manipulating stock prices and submitting fraudulent claims for allergy and coronavirus testing from which he allegedly made US$69 million.

Health authorities around the world have allowed surgical implants to go on the market — and be placed inside patients — despite a lack of adequate testing, an investigation by the International Consortium of Investigative Journalists (ICIJ) has found.